{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:25:38Z","timestamp":1795209938827,"version":"4.10.3"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Multiple myeloma is a plasma cell malignancy associated with heterogeneous clinical outcomes. The majority of patients are diagnosed during their seventh decade and often present with age-related comorbidities and organ dysfunction. Myeloma therapeutic landscape is rapidly evolving with the introduction of immune-based therapies, including monoclonal and bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies targeting CD38, BCMA, and GPRC5D. These novel therapies have led to deeper and more durable responses and have raised the possibility of functional or definitive cure. However, older and frail patients continue to experience poorer outcomes, higher toxicity rates, and substantial treatment attrition, representing a major unmet clinical challenge. In this review, we discuss current approaches to the assessment and management of frailty in patients with multiple myeloma, with a focus on optimizing frontline therapy and treatment at relapse in the era of the possible achievement of a cure. We highlight emerging data on cellular therapies in this population and the importance of individualized, goal-directed treatment strategies aimed at balancing efficacy, tolerability, and quality of life.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000850","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:01:17Z","timestamp":1790366477000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tailoring Therapy for Frail and Elderly Myeloma Patients"],"prefix":"10.1097","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-4732","authenticated-orcid":false,"given":"Thomas","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6198-3405","authenticated-orcid":false,"given":"Raphael E.","family":"Szalat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20261120","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"R2-20261120","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term ( > \/ = 5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"R3-20261120","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"key":"R4-20261120","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/bloodadvances.2025015973","article-title":"Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed\/refractory multiple myeloma","volume":"9","author":"Adegbite","year":"2025","journal-title":"Blood Adv"},{"key":"R5-20261120","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.jgo.2023.101628","article-title":"Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Akhtar","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"R6-20261120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41408-025-01297-7","article-title":"Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium","volume":"15","author":"Pasvolsky","year":"2025","journal-title":"Blood Cancer J"},{"key":"R7-20261120","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"R8-20261120","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"R9-20261120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"R10-20261120","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant- ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"R11-20261120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41408-023-00883-x","article-title":"Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","volume":"13","author":"McCurdy","year":"2023","journal-title":"Blood Cancer J"},{"key":"R12-20261120","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clml.2025.03.004","article-title":"Survival, years of life lost and attrition rates in multiple myeloma patients in France","volume":"25","author":"Perrot","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R13-20261120","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-025-01311-y","article-title":"Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period","volume":"15","author":"Rodriguez-Lobato","year":"2025","journal-title":"Blood Cancer J"},{"key":"R14-20261120","doi-asserted-by":"crossref","first-page":"979111","DOI":"10.3389\/fphar.2023.979111","article-title":"Treatment attrition rates and relevant risk factors in multiple myeloma: a real-world study in China","volume":"14","author":"Tang","year":"2023","journal-title":"Front Pharmacol"},{"key":"R15-20261120","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMra2301292","article-title":"Frailty in older adults. Reply","volume":"391","author":"Kim","year":"2024","journal-title":"N Engl J Med"},{"key":"R16-20261120","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"R17-20261120","doi-asserted-by":"crossref","first-page":"e30169","DOI":"10.1097\/MD.0000000000030169","article-title":"Risk factors for frailty in older adults","volume":"101","author":"Wang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R18-20261120","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(19)31786-6","article-title":"Frailty: implications for clinical practice and public health","volume":"394","author":"Hoogendijk","year":"2019","journal-title":"Lancet"},{"key":"R19-20261120","doi-asserted-by":"crossref","first-page":"101751","DOI":"10.1016\/j.jgo.2024.101751","article-title":"Geriatric assessment- identified impairments and frailty in adults with cancer younger than 65: an opportunity to optimize oncology care","volume":"15","author":"Pergolotti","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"R20-20261120","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/cncr.34196","article-title":"Frail young adult cancer survivors experience poor health-related quality of life","volume":"128","author":"Pranikoff","year":"2022","journal-title":"Cancer"},{"key":"R21-20261120","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.21.00194","article-title":"Physiologic frailty and neurocognitive decline among young-adult childhood cancer survivors: a prospective study from the St Jude Lifetime Cohort","volume":"39","author":"Williams","year":"2021","journal-title":"J Clin Oncol"},{"key":"R22-20261120","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.23.00933","article-title":"Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update","volume":"41","author":"Dale","year":"2023","journal-title":"J Clin Oncol"},{"key":"R23-20261120","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood.2022017635","article-title":"How I treat multiple myeloma in geriatric patients","volume":"143","author":"Facon","year":"2024","journal-title":"Blood"},{"key":"R24-20261120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","article-title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"key":"R25-20261120","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1016\/S2666-7568(22)00172-6","article-title":"Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study","volume":"3","author":"Efficace","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"R26-20261120","doi-asserted-by":"crossref","first-page":"102051","DOI":"10.1016\/j.jgo.2024.102051","article-title":"Evaluating concordance between International Myeloma Working Group (IMWG) frailty score and Simplified Frailty Scale among older adults with multiple myeloma","volume":"15","author":"Gahagan","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"R27-20261120","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/10428194.2024.2340052","article-title":"Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL)","volume":"65","author":"Haider","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"R28-20261120","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jgo.2018.10.010","article-title":"Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older","volume":"10","author":"Murillo","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"R29-20261120","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/imj.16049","article-title":"The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia","volume":"53","author":"Sim","year":"2023","journal-title":"Intern Med J"},{"key":"R30-20261120","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"key":"R31-20261120","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/10428194.2024.2419375","article-title":"Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice","volume":"66","author":"Pianko","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"R32-20261120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: a population-based cohort study","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"key":"R33-20261120","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/blood.2024025868","article-title":"Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma","volume":"145","author":"Smits","year":"2025","journal-title":"Blood"},{"key":"R34-20261120","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.1182\/bloodadvances.2023011019","article-title":"More intensive therapy as more effective treatment for frail patients with multiple myeloma [corrected]","volume":"7","author":"DuMontier","year":"2023","journal-title":"Blood Adv"},{"key":"R35-20261120","doi-asserted-by":"crossref","first-page":"101781","DOI":"10.1016\/j.jgo.2024.101781","article-title":"Understanding health outcome preferences of older adults diagnosed with multiple myeloma","volume":"15","author":"Maheshwari","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"R36-20261120","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S1470-2045(18)30348-6","article-title":"Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer","volume":"19","author":"Soto-Perez-de-Celis","year":"2018","journal-title":"Lancet Oncol"},{"key":"R37-20261120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-023-00815-9","article-title":"Group EQoL. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development","volume":"13","author":"Forde","year":"2023","journal-title":"Blood Cancer J"},{"key":"R38-20261120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14236007","article-title":"The reporting, use, and validity of patient-reported outcomes in multiple myeloma in clinical trials: a systematic literature review","volume":"14","author":"Salek","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R39-20261120","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jtct.2025.06.030","article-title":"Assessing quality of life and symptoms in transplantation and CAR-T recipients: expert panel recommendations from the Survivorship Special Interest Group of ASTCT","volume":"31","author":"Banerjee","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"R40-20261120","doi-asserted-by":"crossref","first-page":"e876","DOI":"10.1016\/S2352-3026(25)00256-X","article-title":"Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial","volume":"12","author":"Dimopoulos","year":"2025","journal-title":"Lancet Haematol"},{"key":"R41-20261120","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/ lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"key":"R42-20261120","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"26","author":"Mateos","year":"2025","journal-title":"Lancet Oncol"},{"key":"R43-20261120","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R44-20261120","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"key":"R45-20261120","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"R46-20261120","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41375-024-02506-1","article-title":"Daratumumab plus lenalidomide\/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study","volume":"39","author":"Moreau","year":"2025","journal-title":"Leukemia"},{"key":"R47-20261120","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/ejh.14392","article-title":"Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes","volume":"114","author":"Perrot","year":"2025","journal-title":"Eur J Haematol"},{"key":"R48-20261120","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S1470-2045(25)00280-3","article-title":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial","volume":"26","author":"Manier","year":"2025","journal-title":"Lancet Oncol"},{"issue":"supplement 1","key":"R49-20261120","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/blood-2025-498","article-title":"Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: ad-hoc analysis of the phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept","volume":"146","author":"Castiaux","year":"2025","journal-title":"Blood"},{"key":"R50-20261120","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3324\/haematol.2024.287200","article-title":"Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant- ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial","volume":"110","author":"Manier","year":"2025","journal-title":"Haematologica"},{"key":"R51-20261120","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","article-title":"Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial","volume":"12","author":"Askeland","year":"2025","journal-title":"Lancet Haematol"},{"key":"R52-20261120","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/cncr.34760","article-title":"A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma","volume":"129","author":"Grant","year":"2023","journal-title":"Cancer"},{"key":"R53-20261120","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"issue":"supplement 1","key":"R54-20261120","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/blood-2025-367","article-title":"A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial, cohort a","volume":"146","author":"Manier","year":"2025","journal-title":"Blood"},{"key":"R55-20261120","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"R56-20261120","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/hematology.2022000346","article-title":"Fitness and frailty in myeloma","volume":"2022","author":"Pawlyn","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R57-20261120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/hematology.2021000231","article-title":"Treatment of older adult or frail patients with multiple myeloma","volume":"2021","author":"Grant","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R58-20261120","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"key":"R59-20261120","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study","volume":"23","author":"Richardson","year":"2022","journal-title":"Lancet Oncol"},{"key":"R60-20261120","doi-asserted-by":"crossref","first-page":"E423","DOI":"10.1002\/ajh.26319","article-title":"Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed\/refractory multiple myeloma: ICARIA-MM subgroup analysis","volume":"96","author":"Schjesvold","year":"2021","journal-title":"Am J Hematol"},{"key":"R61-20261120","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"key":"R62-20261120","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"R63-20261120","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"key":"R64-20261120","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1182\/bloodadvances.2020001965","article-title":"Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and\/or refractory multiple myeloma","volume":"4","author":"Facon","year":"2020","journal-title":"Blood Adv"},{"key":"R65-20261120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41408-025-01256-2","article-title":"Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis","volume":"15","author":"Dong","year":"2025","journal-title":"Blood Cancer J"},{"key":"R66-20261120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"R67-20261120","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"R68-20261120","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"R69-20261120","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"R70-20261120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"key":"R71-20261120","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"R72-20261120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.6004\/jadpro.2023.14.4.4","article-title":"Management of ocular toxicity in patients receiving belantamab mafodotin","volume":"14","author":"Lu","year":"2023","journal-title":"J Adv Pract Oncol"},{"key":"R73-20261120","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","article-title":"Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial","volume":"11","author":"Delforge","year":"2024","journal-title":"Lancet Haematol"},{"key":"R74-20261120","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","article-title":"Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed\/refractory multiple myeloma","volume":"30","author":"Davis","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R75-20261120","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"R76-20261120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"R77-20261120","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"R78-20261120","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"supplement 1","key":"R79-20261120","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2025-136","article-title":"Real-world outcomes with elranatamab in multiple myeloma: a multi-center analysis from the United States Multiple Myeloma Immunotherapy Consortium","volume":"146","author":"Portuguese","year":"2025","journal-title":"Blood"},{"issue":"supplement 1","key":"R80-20261120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2025-137","article-title":"Talquetamab for relapsed\/refractory multiple myeloma: real-world outcomes from the US Multiple Myeloma Immunotherapy Consortium","volume":"146","author":"Pasvolsky","year":"2025","journal-title":"Blood"},{"key":"R81-20261120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/2643-3230.BCD-24-0354","article-title":"Real-World experience with teclistamab for relapsed\/refractory multiple myeloma from the US Myeloma Immunotherapy Consortium","volume":"6","author":"Razzo","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"R82-20261120","article-title":"Safety and tolerability of CAR T-cell therapy in patients with end-stage kidney disease on hemodialysis: a case series","author":"Ahmed","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R83-20261120","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1182\/bloodadvances.2025016059","article-title":"Teclistamab for patients with heavily pretreated relapsed\/refractory multiple myeloma and renal impairment","volume":"9","author":"Dima","year":"2025","journal-title":"Blood Adv"},{"issue":"supplement 1","key":"R84-20261120","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2025-827","article-title":"Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)","volume":"146","author":"Joiner","year":"2025","journal-title":"Blood"},{"key":"R85-20261120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.clml.2023.11.001","article-title":"Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the Phase II MajesTEC-1 Study","volume":"24","author":"Martin","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R86-20261120","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/bjh.19346","article-title":"Impact of elranatamab on quality of life: patient-reported outcomes from MagnetisMM-3","volume":"204","author":"Mohty","year":"2024","journal-title":"Br J Haematol"},{"key":"R87-20261120","doi-asserted-by":"crossref","first-page":"e35927","DOI":"10.1002\/cncr.35927","article-title":"Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"131","author":"Schinke","year":"2025","journal-title":"Cancer"},{"key":"R88-20261120","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"key":"R89-20261120","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.clml.2025.04.002","article-title":"Feasibility and safety of outpatient model for administration of bispecific antibodies: proceedings from an International Myeloma Society 21st Annual Meeting oral abstract","volume":"25","author":"Scott","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"supplement 1","key":"R90-20261120","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2025-4064","article-title":"Fixed-duration teclistamab and talquetamab for frail patients with newly diagnosed multiple myeloma: the EMN37 Fitfix study","volume":"146","author":"Zweegman","year":"2025","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:00:19Z","timestamp":1795208419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":90,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000850","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-04-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}